FDA Makes It Official: Action On Human Growth Hormone Will Wait
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz presents FDA's deferral of a decision on Omnitrope application as a tentative approval. The agency has completed its review of the recombinant human growth hormone product and did not identify any deficiencies, Sandoz says.
You may also be interested in...
Sandoz Sues FDA For Inaction On Omnitrope NDA
Lawsuit seeks a court declaration that the 505(b)(2) pathway “can be used for protein-based biologic drugs regulated under Section 505 of the FD&C Act.”
Sandoz Sues FDA For Inaction On Omnitrope NDA
Lawsuit seeks a court declaration that the 505(b)(2) pathway “can be used for protein-based biologic drugs regulated under Section 505 of the FD&C Act.”
Novartis Boosts Sandoz Generic Business With Acquisition Of Eon, Hexal
Addition of U.S., German companies will make Sandoz the global leader in generic sales, with combined 2004 pro forma revenues of $5.1 bil., Novartis says. Acquisition will enable Sandoz to become the "preferred partner" for "authorized" generic deals and to play a leading role in development of follow-on biologics.